CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
January 10, 2022 06:30 ET | Cullinan Oncology, Inc.
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
Logo.jpg
INVECTYS INC. TO PARTICIPATE IN THE 2022 JP MORGAN HEALTHCARE MEETING AND BIOTECH SHOWCASE, JANUARY 10-19, 2022 
January 05, 2022 09:00 ET | Invectys, Inc.
Houston, Texas, USA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
CO-MasterLogo@4x_300 DPI.png
Cullinan Oncology to Present at Upcoming Virtual Investor Conferences
January 05, 2022 09:00 ET | Cullinan Oncology, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:05 ET | Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc., (NASDAQ: LYEL), a T-cell reprogramming company dedicated to the mastery of T cells to cure patients with...
VIR_logo_large.jpg
Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 16:02 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will present at the 40th Annual J.P....
logo_new.jpg
ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco
January 15, 2020 01:00 ET | ObsEva SA
  Phase 3 linzagolix trials expected to generate additional data in uterine fibroids in Q2:20 with first linzagolix regulatory filing planned for late 2020Enrollment of linzagolix US and EU Phase 3...
logo_new.jpg
ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020
January 07, 2020 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
AskBio-Logo-with-NoTagline_Black_Large.png
AskBio to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 02, 2020 16:53 ET | Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical (AskBio), a fully integrated, clinical-stage adeno-associated virus (AAV) gene therapy company, today...
logo_new.jpg
ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
January 02, 2019 01:00 ET | ObsEva SA
Geneva, Switzerland and Boston – January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
Enable Injections Achieves ISO 13485:2016 Certification to Meet Mounting Demand for Drug-Delivery Device Combination Products
January 08, 2018 06:00 ET | Enable Injections, Inc.
CINCINNATI, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Enable Injections, Inc., developer of the advanced enFuse™ large volume wearable injectors (LVWI) platform for subcutaneous delivery of biologics, has...